Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
OTCMKTS:RHHBY

Roche (RHHBY) Stock Price, News & Analysis

Roche logo
$61.17 +1.55 (+2.60%)
As of 10/23/2026 03:59 PM Eastern

About Roche Stock (OTCMKTS:RHHBY)

Advanced

Key Stats

Today's Range
$59.00
▼
$61.49
50-Day Range
$51.88
▼
$61.17
52-Week Range
$40.07
▼
$61.49
Volume
2.61 million shs
Average Volume
1.39 million shs
Market Capitalization
$389.69 billion
P/E Ratio
N/A
Dividend Yield
1.59%
Price Target
$60.00
Consensus Rating
Moderate Buy

Company Overview

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions. Roche also operates a diagnostics business that provides in-vitro diagnostic systems, laboratory tests, tissue-based diagnostics and digital health solutions for hospitals, laboratories, physicians and patients.

Roche serves healthcare providers and patients worldwide through operations and commercial activities across numerous geographic markets. Its global business includes Genentech in the United States, which operates as a member of the Roche Group and supports the company’s pharmaceutical research and development activities.

Thomas Schinecker has served as Roche’s chief executive officer since 2023, while Severin Schwan is chairman of the company’s board of directors. Roche’s shares trade in Switzerland, and its American depositary receipts trade on the over-the-counter market under the symbol RHHBY.

AI Generated. May Contain Errors.

Roche Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

RHHBY MarketRank™: 
2.70757880617 of 5 stars

Roche scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Roche has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 8 buy ratings, 5 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Roche is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Roche has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Roche's stock forecast and price target.
  • Earnings Growth

    Earnings for Roche are expected to grow by 7.28% in the coming year, from $3.02 to $3.24 per share.

  • Price to Earnings Growth Ratio

    Roche has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Roche has a P/B Ratio of 8.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.05% of the float of Roche has been sold short.
  • Short Interest Ratio / Days to Cover

    Roche has a short interest ratio ("days to cover") of 1.05, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Roche has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Roche pays a meaningful dividend of 1.59%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Roche does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Roche will have a dividend payout ratio of 29.94% next year. This indicates that Roche will be able to sustain or increase its dividend.

  • Read more about Roche's dividend.
  • News Sentiment

    Roche has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Roche this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for RHHBY on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Roche insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Roche has minimal institutional ownership at this time.

  • Read more about Roche's insider trading history.
Receive RHHBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RHHBY Stock News Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Roche (OTCMKTS:RHHBY) Sets New 12-Month High - Here's Why
Illustration of a semiconductor wafer in a manufacturing facility with a digital world map showing global network connections.
There's a New Q in Town: Invesco's ETF Targets International Innovators (RHHBY)
Invesco recently launched QQI, an ETF tracking the Nasdaq International Innovators 100 Index, offering tech- and healthcare-heavy exposure to non-U.S. growth companies with higher costs and lower liquidity than QQQ.
See More Headlines

RHHBY Stock Analysis - Frequently Asked Questions

Roche's stock was trading at $51.57 at the beginning of the year. Since then, RHHBY stock has increased by 18.6% and is now trading at $61.17.

Roche subsidiaries include these companies: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and more.

Top institutional investors of Roche include GAMMA Investing LLC and Woodstock Corp.

Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Roche investors own include Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Bristol Myers Squibb (BMY), Intel (INTC) and Walt Disney (DIS).

Company Calendar

Today
10/25/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:RHHBY
CIK
N/A
Employees
103,249
Year Founded
1896

Price Target and Rating

High Price Target
$63.00
Low Price Target
$57.00
Potential Upside/Downside
-1.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
20.25
P/E Growth
3.87
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.69
Current Ratio
1.23
Quick Ratio
0.95

Sales & Book Value

Annual Sales
$76.45 billion
Price / Sales
5.10
Cash Flow
$3.60 per share
Price / Cash Flow
16.99
Book Value
$7.18 per share
Price / Book
8.52

Miscellaneous

Outstanding Shares
6,370,540,000
Free Float
N/A
Market Cap
$389.69 billion
Optionable
Not Optionable
Beta
0.45

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:RHHBY) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners